EULAR response criteria for polymyalgia rheumatica: Results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT)

B. F. Leeb, H. A. Bird, G. Nesher, I. Andel, W. Hueber, D. Logar, C. M. Montecucco, J. Rovensky, J. Sautner, M. Sonnenblick

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To develop response criteria for polymyalgia rheumatica (PMR) for monitoring treatment and comparing alternative treatments regimens. Methods: 76 patients, mean (SD) age 68.7 (7.7) years, were enrolled. Corticosteroids, and non-steroidal anti-inflammatory drugs (NSAIDs) were the only drugs allowed during the observation period. Erythrocyte sedimentation rate (ESR), C reactive protein (CRP), α2 globulin, serum iron, pain, physician's global assessment (PGA), morning stiffness (MST), muscle tenderness (MT), myalgia, and the elevation of upper limbs (EUL) were determined regularly. The daily corticosteroid and NSAID doses as the corticosteroid response time were recorded. To ensure evaluation of an adequate number of patients (n = 57) week 24 was chosen for final analysis. Results: ESR, CRP, α2 globulin, pain, PGA, MST, myalgia, MT, and EUL showed significant improvement (p2 globulin (p = 0.13), MST (p = 0.1), and MT (p = 0.07) were independent of pain, but myalgia (p

Original languageEnglish
Pages (from-to)1189-1194
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume62
Issue number12
DOIs
Publication statusPublished - Dec 2003

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Fingerprint Dive into the research topics of 'EULAR response criteria for polymyalgia rheumatica: Results of an initiative of the European Collaborating Polymyalgia Rheumatica Group (subcommittee of ESCISIT)'. Together they form a unique fingerprint.

Cite this